A Phase I, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD20
A Study of OBT076 in Women with Recurring and/or Metastatic Solid Tumors
Sponsor: Oxford BioTherapeutics
Enrolling: Female Patients Only
IRB Number: AAAS3724
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an Investigational Drug, which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors.
This study is closed
Ryan Moy, MD
Do You Qualify?
Are you a female, 18 years of age or older? Yes No
Do you have a solid tumor that continues to grow, for which standard therapy is not available or is no longer effective? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator